Aimwell Partners

continuous intelligence system that is actively watching regulatory, clinical, and competitive environments right now.

$AIMN

[ACCESS Newswire @AccesswireNews]

$AIMN AimwellBio Opens a Door Most People Will Not Be Allowed Through, And Healthcare's Sharpest Professionals Are ... https://t.co/KD1oZA89yP

[Aimwell Partners @AimwellPartners]

AimwellBio Opens a Door Most People Will Not Be Allowed Through, And Healthcare's Sharpest Professionals Are Already Walking In

$AIMN

https://t.co/nicBwraNOe

[Aimwell Bio @AimwellBIO]

https://t.co/49779cB0ra : $AIMN

[Aimwell Bio @AimwellBIO]

https://t.co/49779cB0ra : $AIMN

[Aimwell Bio @AimwellBIO]

This is what a verified contributor looks like inside AimwellBio.✅
Christopher A. Jones, PhD, MSc, FRSM. (top 3% of all AIMN contributors). 80 publications. 1,487 citations. Founding Cohort is still forming. Observer access is open today. $AIMN
https://t.co/vyHDkTtPBh

[Aimwell Partners @AimwellPartners]

$AIMN

[Aimwell Bio @AimwellBIO]

The AimwellBio founding cohort is taking shape, and the caliber speaks for itself.
Welcoming Christopher A. Jones, PhD,
Managing Director, Ventures at University of Vermont Health Network.
Decision intelligence is being built by people who actually shape healthcare. $AIMN

[Aimwell Bio @AimwellBIO]

The AimwellBio founding cohort is taking shape, and the caliber speaks for itself.
Welcoming Christopher A. Jones, PhD,
Managing Director, Ventures at University of Vermont Health Network.
Decision intelligence is being built by people who actually shape healthcare. $AIMN

[Aimwell Partners @AimwellPartners]

The next trillion-dollar AI market may not be chatbots.
It may be VERIFIED intelligence in healthcare.

DR’s need trusted clinical infrastructure.

Aimwellbio is building a source-validated intelligence layer designed for the future of medicine, biotech and patient safety.

$AIMN

[Aimwell Bio @AimwellBIO]

The AI isn't the problem.
The thing missing above the AI is. And it's already cost someone their job this quarter.
60 seconds. 👇 $AIMN https://t.co/JAWMDUiVl8 #watch

[Aimwell Partners @AimwellPartners]

https://t.co/4lt7nyKGl2
$AIMN

[Aimwell Partners @AimwellPartners]

The Quiet Restructuring of Healthcare Intelligence: Why the Industry is Moving Toward Verified Professional Networks Over Anonymous AI
$AIMN

https://t.co/xXnosuph7G

[Aimwell Partners @AimwellPartners]

Healthcare AI is entering a new phase.

The question is no longer “Can AI generate answers?”

It’s:
“Can the clinical signal actually be verified?”

That’s the foundation behind FHIN. $AIMN

$AIMN #HealthcareAI #HealthTech #AI

[Aimwell Bio @AimwellBIO]

Did you take time to check the new updates on the https://t.co/vyHDkTtPBh website? More details coming soon

[Aimwell Partners @AimwellPartners]

Inside AimwellBio's Federated Health Intelligence Network: Verified Clinical Intelligence Model Gains Attention Among Physicians
$AIMN

https://t.co/jotN7DaC9x

[Aimwell Partners @AimwellPartners]

Most healthcare AI platforms are still answering questions.

AimwellBio is building the layer that verifies whether the answers were real in the first place.

Doctors saw the gap first.

Neurology. CTE. Alzheimer’s. Parkinson’s. Dementia.

The signal layer is expanding.

$AIMN

[Aimwell Partners @AimwellPartners]

The Doctors Saw It First. Then the Chiropractors Asked. Now AimwellBio is Adding the Four Signals Every Family in America is Quietly Searching For.

$AIMN

https://t.co/RZ5X67iDpc

[Aimwell Partners @AimwellPartners]

Most AI tells you something.

FHIN is built to tell you whether it’s true.

Clinical signals. Regulatory movement. Trial shifts. Competitive intelligence.

Verified. Contextualized. Traceable.
That’s the infrastructure gap $AIMN is solving

https://t.co/u9Gv2fqpv2

[Aimwell Partners @AimwellPartners]

Aimwell Partners Brand, AimwellBio Announces Expanded FHIN Intelligence Framework, Early Demo Feedback, and New AIMN Development Milestones

https://t.co/u9Gv2fqpv2

$AIMN

[Aimwell Partners @AimwellPartners]

Had to RE-update OTC markets profile page to reflect current information. Evidently, it didn’t stick with the new company description the last time (few weeks ago) the description etc should be updated in 1-2 business days.

Thanks for your attention to this matter.
$AIMN

[Aimwell Partners @AimwellPartners]

Most organizations don’t have an AI problem.
They have a “we saw it too late” problem.

FDA actions. Trials. Patents. Shortages.

The signal was already there. The question Did your organization see it in time?

$AIMN

https://t.co/Ux51CAq6CK